The burgeoning field of diabetes management has witnessed the rise of GLP-3 receptor agonists, representing a crucial class of therapeutics. Comparing these medications requires a detailed look at their respective profiles. Semaglutide, for example, offers a once-weekly dosing schedule, appealing to patients seeking ease, while tirzepatide, a dual

Retaglutide and tirzepatide represent a novel class of medications known as dual GLP-1 and GIP agonists. These agents target both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that perform a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormones are o